BriaCell Announces Non-Brokered Private Placement

BriaCell Therapeutics Corp. (OTCQB:BCTXF)(TSX VENTURE:BCT) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to $1,500,000. Under the Offering, each Unit shall consist of one common …

BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer

BERKELEY, CA and VANCOUVER, BC–(Marketwired – May 18, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce that it has signed a definitive agreement with Cancer Insight, LLC, a cancer-vaccine focused clinical research organization (CRO), to initiate Phase I/IIa clinical studies and regulatory filings for BriaVax™, …

BRIACELL ADDS U.S. BIOTECH VETERAN TO ITS BOARD OF DIRECTORS

Berkeley, CA and Vancouver, BC – Tuesday May 10, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) today announced a change to its board of directors. BriaCell is pleased to welcome the appointment of Mr. Martin Schmieg to its Board of Directors. Mr. Schmieg, with 35 years of business experience, …

BriaCell Completes Previously Announced Investment with Leading U.S. Biotech Fund and Non-Brokered Private Placement

Berkeley, CA and Vancouver, BC – May 3, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placements of units totaling gross proceeds of C$1,275,000. BriaCell intends to use the proceeds from the financings …

BriaCell Announces Non-Brokered Private Placement

BriaCell Therapeutics Corp. (TSX VENTURE:BCT)(OTCQB:BCTXF) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to C$600,000. The Offering is in addition to the Company’s proposed strategic …

BriaCell Announces Proposed Investment by Leading US Biotech Fund – Company Plans to Seek NASDAQ Uplisting –

Berkeley, CA and Vancouver, BC – April 22, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has entered into an agreement with a leading US biotechnology fund for an investment of C$650,000. The subscription agreement of units (“Units”) is priced at C$0.19, each …

BriaCell Files a Patent Application to Protect Additional Cancer Vaccines with Genetic Features Thought to Promote Strong Anti-Tumor Activity

– Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 – Berkeley, CA and Vancouver, BC – April 12, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office …

BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter

BERKELEY, CA and VANCOUVER, BC–(Marketwired – April 05, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)(TSX VENTURE: BCT) (BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has spent a great deal of time and …

BriaCell Discovers Gene Signature of BriaVax(TM) Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial

BERKELEY, CA and VANCOUVER, BC–(Marketwired – March 29, 2016) – BriaCell Therapeutics Corp.(“BriaCell” or the “Company”)(TSX VENTURE: BCT) (BCTXF) is very pleased to announce that it has discovered a gene signature potentially explaining why its BriaVax™ cancer vaccine was exceptionally efficacious in a clinical trial subject with stage IV breast cancer. Data will be presented at the Annual …

BriaCell Announces Senior Management Change

VANCOUVER, BRITISH COLUMBIA–(Marketwired – Mar 24, 2016) – BriaCell Therapeutics Corp. (BCTXF) (TSX VENTURE:BCT) (the “Company“) announces that Dr. Joseph Wagner has resigned his positions as President and Chief Executive Officer of the Company, effective immediately, in order to pursue other opportunities. Dr. Wagner has also stepped down from the Board. Mr. Rahoul Sharan, Director …